BeOne Medicines (NASDAQ:ONC – Get Free Report) and Redhill Biopharma (NASDAQ:RDHL – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Volatility & Risk
BeOne Medicines has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.83, indicating that its stock price is 383% more volatile than the S&P 500.
Valuation & Earnings
This table compares BeOne Medicines and Redhill Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $3.81 billion | 10.05 | -$644.79 million | $0.51 | 633.14 |
| Redhill Biopharma | $8.04 million | 0.68 | -$8.27 million | $486.75 | 0.00 |
Redhill Biopharma has lower revenue, but higher earnings than BeOne Medicines. Redhill Biopharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for BeOne Medicines and Redhill Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 1 | 12 | 0 | 2.79 |
| Redhill Biopharma | 1 | 0 | 0 | 0 | 1.00 |
BeOne Medicines currently has a consensus price target of $365.79, suggesting a potential upside of 13.28%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, equities analysts plainly believe BeOne Medicines is more favorable than Redhill Biopharma.
Profitability
This table compares BeOne Medicines and Redhill Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
| Redhill Biopharma | N/A | N/A | N/A |
Insider & Institutional Ownership
48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
BeOne Medicines beats Redhill Biopharma on 10 of the 14 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Redhill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
